Mobic (Meloxicam)

Meloxicam works by reversibly inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, with a preference for COX‑2. This inhibition reduces the production of prostaglandins, which are key mediators of inflammation, pain, and fever, thereby providing analgesic and anti‑inflammatory effects.

The dose of Mobic is individualized by the prescribing healthcare professional based on the specific indication, severity of symptoms, patient weight, renal and hepatic function, and any concomitant medications. No fixed regimen is provided here; the prescriber sets the appropriate dosage.

Safety data for meloxicam in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To order Mobic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Mobic (meloxicam) offers a longer half‑life than many NSAIDs like ibuprofen, allowing once‑daily dosing for many patients. It also shows a higher selectivity for COX‑2, which may reduce gastrointestinal side effects compared with non‑selective NSAIDs, though cardiovascular and renal risks remain similar.

Mobic injection should be stored at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Follow any additional instructions on the label to maintain product stability.

Mobic is supplied as a sterile injectable solution for intramuscular injection. The healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and according to the prescribed amount.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, acute renal failure, hepatic injury, and increased cardiovascular events like myocardial infarction or stroke. Patients should be monitored for signs of these conditions and discontinue use if they occur.

Mobic should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration, severe renal or hepatic impairment, uncontrolled hypertension, and patients with a history of cardiovascular thrombotic events unless specifically directed by a physician.